Advertisement
ARVN vs FHTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and FHTX is a StrongBuy.
ARVN's RSI Indicator ascends from oversold territory
The RSI Oscillator for ARVN moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 27 of the 32 cases the stock moved higher. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ARVN as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for ARVN just turned positive on October 19, 2026. Looking at past instances where ARVN's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ARVN crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ARVN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.879) is normal, around the industry mean (2.988). P/E Ratio (25.183) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FHTX sees its Stochastic Oscillator ascends from oversold territory
On October 20, 2026, the Stochastic Oscillator for FHTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In 55 of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for FHTX just turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 34 of 36 cases over the following month. The odds of a continued upward trend are 90%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHTX as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.495) is normal, around the industry mean (2.988). P/E Ratio (-2.061) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARVN | FHTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 83 | 100 | |
PRICE GROWTH RATING 1..100 | 73 | 94 | |
P/E GROWTH RATING 1..100 | 48 | 8 | |
SEASONALITY SCORE 1..100 | 32 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FHTX's Valuation (22) in the null industry is significantly better than the same rating for ARVN (88) in the Biotechnology industry. This means that FHTX’s stock grew significantly faster than ARVN’s over the last 12 months.
FHTX's Profit vs Risk Rating (100) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that FHTX’s stock grew similarly to ARVN’s over the last 12 months.
ARVN's SMR Rating (83) in the Biotechnology industry is in the same range as FHTX (100) in the null industry. This means that ARVN’s stock grew similarly to FHTX’s over the last 12 months.
ARVN's Price Growth Rating (73) in the Biotechnology industry is in the same range as FHTX (94) in the null industry. This means that ARVN’s stock grew similarly to FHTX’s over the last 12 months.
FHTX's P/E Growth Rating (8) in the null industry is somewhat better than the same rating for ARVN (48) in the Biotechnology industry. This means that FHTX’s stock grew somewhat faster than ARVN’s over the last 12 months.
| ARVN | FHTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | N/A |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| Advances ODDS (%) | 3 days ago 80% | 2 days ago 86% |
| Declines ODDS (%) | 9 days ago 81% | 10 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARVN’s FA Score shows that 0 FA rating(s) are green while FHTX’s FA Score has 2 green FA rating(s).
- ARVN’s FA Score: 0 green, 5 red.
- FHTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARVN’s TA Score shows that 5 TA indicator(s) are bullish while FHTX’s TA Score has 4 bullish TA indicator(s).
- ARVN’s TA Score: 5 bullish, 4 bearish.
- FHTX’s TA Score: 4 bullish, 4 bearish.
Price Growth
ARVN (@Biotechnology) experienced а +10.78% price change this week, while FHTX (@Biotechnology) price change was +10.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
ARVN is expected to report earnings on Nov 04, 2026.
FHTX is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FHTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with ARVN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To FHTX | 1D Price Change % | ||
|---|---|---|---|---|
| FHTX | 100% | +1.49% | ||
| ARVN - FHTX | 42% Loosely correlated | -1.37% | ||
| LCTX - FHTX | 40% Loosely correlated | -2.17% | ||
| DNLI - FHTX | 39% Loosely correlated | -1.32% | ||
| VYGR - FHTX | 39% Loosely correlated | -7.76% | ||
| IMTX - FHTX | 39% Loosely correlated | +2.40% | ||
More | ||||